Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.

[1]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[2]  R. Dittus,et al.  Influenza– and Respiratory Syncytial Virus–Associated Morbidity and Mortality in the Nursing Home Population , 2003, Journal of the American Geriatrics Society.

[3]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[4]  A. Osterhaus,et al.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. , 2002, Vaccine.

[5]  M. Plante,et al.  Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. , 2001, Vaccine.

[6]  David N. Taylor,et al.  Safety and Immunogenicity of a Proteosome-Shigella flexneri 2a Lipopolysaccharide Vaccine Administered Intranasally to Healthy Adults , 2001, Infection and Immunity.

[7]  J. Mcghee,et al.  Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.

[8]  K. Neuzil,et al.  Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. , 2000, Vaccine.

[9]  Lihan K. Yan,et al.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. , 2000, The Journal of infectious diseases.

[10]  R. Betts,et al.  Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. , 1999, Vaccine.

[11]  W. Gruber,et al.  Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. , 1999 .

[12]  I. Longini,et al.  Estimates of the US health impact of influenza. , 1993, American journal of public health.

[13]  R. Couch,et al.  Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. , 1993, The Journal of infectious diseases.

[14]  B. Murphy,et al.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory , 1991, Journal of clinical microbiology.

[15]  Gary J. Nabel,et al.  New Generation Vaccines , 1990 .

[16]  E. Lennette,et al.  Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections , 1989 .

[17]  B. Murphy,et al.  Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum , 1987, Journal of clinical microbiology.

[18]  B. Murphy,et al.  Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus , 1986, Journal of clinical microbiology.

[19]  P. Wright,et al.  Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. , 1986, The Journal of infectious diseases.

[20]  B. Murphy,et al.  Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine , 1986, Journal of clinical microbiology.

[21]  B. Murphy,et al.  ADVANTAGE OF LIVE ATTENUATED COLD-ADAPTED INFLUENZA A VIRUS OVER INACTIVATED VACCINE FOR A/WASHINGTON/80 (H3N2) WILD-TYPE VIRUS INFECTION , 1984, The Lancet.

[22]  B. Murphy,et al.  Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory , 1983, Infection and immunity.

[23]  J. Mullooly,et al.  Impact of epidemic type A influenza in a defined adult population. , 1980, American journal of epidemiology.

[24]  P. Small,et al.  Influenza antibody response following aerosal administration of inactivated virus. , 1970, American journal of epidemiology.

[25]  D. Fedson,et al.  Antibody responses in serum and nasal secretions according to age of recipient and method of administration of A2-Hong Kong-68 inactivated influenza virus vaccine. , 1970, Journal of immunology.

[26]  E. Hume,et al.  Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine. , 1969, Journal of immunology.

[27]  H. Maassab,et al.  Biologic and immunologic characteristics of cold-adapted influenza virus. , 1969, Journal of immunology.

[28]  J. Kasel,et al.  Influenza Antibody in Human Respiratory Secretions after Subcutaneous or Respiratory Immunization with Inactivated Virus , 1968, Nature.

[29]  J. Treanor,et al.  Immune correlates of protection against influenza in the human challenge model. , 2003, Developments in biologicals.

[30]  W. Dupont,et al.  A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. , 1994, The Journal of infectious diseases.